【文/观察者网专栏作者 心智观察所】 想象这样一个场景：在一间恒温、无菌的实验室里，几万个来自老鼠胚胎或人类干细胞的脑细胞被小心 地安置在一个指甲盖大小的芯片上。它们没有眼睛去看屏幕，没有手去操控手柄，甚至没有一个完整的 身体——却成功地玩起了上世纪70年代风靡全球的电子游戏《Pong》（乒乓）。更令人惊讶的是，它 们不仅会玩，还在几分钟内学会了如何打得更好。 这并非科幻小说中的桥段，而是2022年由澳大利亚初创公司Cortical Labs联合多所高校发表在 《Neuron》期刊上的一项真实实验。研究团队将这套系统命名为"DishBrain"（培养皿大脑），并首次证 明：即使脱离了生物体，活体神经元也能在虚拟环境中感知信息、做出反应，并通过反馈机制实现学 习。这一发现不仅挑战了我们对"智能"和"意识"的传统理解，也为未来神经科学、药物研发乃至新型计 算范式打开了全新的可能性。 神经元如何"看见"和"移动"？ 那么，神经元如何"知道"球在哪里？又如何"控制"球拍？ 近年来，随着大语言模型的爆发式发展和生成式人工智能的广泛应用，人们一度认为硅基计算——即由 晶体管、芯片和算法构成的传统人工智能——已经牢牢锁定了 ...

■邢萌 日前，胡润研究院发布《2025胡润未来独角兽：中国猎豹企业榜》，304家企业上榜。值得一提的是，有33家2024年登榜 的猎豹企业因"晋级"退出了评选，其中有9家成功上市，2家升级为独角兽企业，19家跻身瞪羚企业，3家被收购。这些分布于 生物科技、人工智能等硬科技领域的企业，借助资本市场搭建的全周期、市场化的"成长阶梯"，顺利完成了从初创期到成熟期 的发展跨越。 近年来，资本市场持续引导私募基金投早、投小、投长期、投硬科技，为早期的科创企业提供"第一桶金"，进而孵化科创 主力军，夯实独角兽企业培育根基；同时，持续畅通科创企业上市渠道，支持优质未盈利企业上市，扩大产业覆盖范围，助力 成熟企业价值跃升；另外，优化上市公司并购重组制度，推动科技资源整合升级，促进产业协同创新。 从更深层次看，猎豹企业的"晋级"，映射出科技创新资本循环的闭环。畅通的上市、并购等退出渠道，为私募基金及其投 资人提供了价值实现与回报变现的关键路径。一次成功的退出，不仅带来本金收回与资本增值，还能激励资本再次投入新的早 期硬科技项目，持续发掘下一个"猎豹"。这就形成了"投资—退出—再投资"的资金循环，增强了驱动科技迭代的金融动力。 ...

数字背后，是传统提取模式日益逼仄的困境：国内血浆站监管趋严，导致资采浆成本飙升；而基于人源血浆的提取模式，理论上永远无法彻底规避未知病 毒跨物种传播的风险。 如今，传统意义上的地下血站基本根除，但非法的血液买卖链条并未消失，而是以一种更隐蔽、更具欺骗性的方式在运作。市场急需一种合规、安全、可 控、可大规模生产的替代来源。 这一次，破局的答案不再来自人，而是来自一只昆虫——蚕。 作为全球最大的人血白蛋白消费国，中国每年需消耗约1000吨，其中超60%长期依赖进口。 鉴于桑蚕丝腺是天然的高效"生物反应器"，位于安吉的链码生物科技有限公司，通过构建标准化的工业方舱养殖体系与家蚕表达系统，实现了重组蛋白的 低成本、可规模化生产。 链码生物创始人吴宇青形容，他们正在"低头开辟新时代"。一场用工业确定性替代生物不确定性的革命，正在链码生物的方舱里发生。 曾被寄予厚望的转基因动物乳腺反应器，虽然单体产量潜力巨大，但牛羊漫长的繁育周期和严苛的动物福利监管，给产业化套上了沉重的时间枷锁，难以 实现快速响应的工业化交付。 植物表达如水稻，则困于不确定性。田间种植成本低廉，但这种开放式系统面临着极高的基因漂移风险，监管压力巨大；且 ...

Core Viewpoint - Yushu Technology's robots are set to appear in the 2026 CCTV Spring Festival Gala, marking the company's third participation in this prestigious event, which significantly boosts its market visibility and commercial orders [1][2]. Group 1: Company Developments - Yushu Technology's robots have previously showcased their capabilities in high-difficulty performances, enhancing public perception of robotic technology [1]. - The competition for the 2026 Spring Festival Gala is intense, with rumors of multiple robotics companies bidding for a spot, indicating Yushu's technological stability and advanced product capabilities [1]. - The company is backed by Xinhua Wenhui, which has strategically invested in Yushu Technology, holding a stake through its investment platform [2]. Group 2: Investment and Strategic Partnerships - Xinhua Wenhui began its investment in Yushu Technology in 2024, contributing 100 million RMB, with Yushu's valuation reaching 12 billion RMB and an anticipated IPO in 2026 [2]. - The partnership between Xinhua Wenhui and leading humanoid robot company UBTECH is aimed at transforming hard technology capabilities into educational service value, exemplified by the "Panda Robot 'Youyou'" project [2]. - Xinhua Wenhui's investment strategy extends beyond robotics, including stakes in various high-tech sectors such as spatial computing and molecular diagnostics, showcasing a diversified investment approach [2][3]. Group 3: Industry Insights - Analysts note that as AI and embodied intelligence enter a commercial phase in 2026, Xinhua Wenhui is evolving from a traditional book distributor to a multifaceted platform with cultural, educational, and hard technology investment capabilities [3]. - The synchronized performance of Yushu Technology's robot clusters at the Spring Festival Gala reflects a broader trend of integrating culture and technology within the industry [3].

Group 1 - The core point of the article highlights the significant impact of the China-South Korea Free Trade Agreement (FTA) on trade facilitation, with the Yanji Customs issuing nearly 2,000 certificates of origin over the past five years, valued at approximately 560 million yuan, effectively reducing trade costs for enterprises engaging with South Korea [1][3][4] Group 2 - Yanji Customs has focused on key areas such as machinery imports and specialty agricultural exports, optimizing customs supervision and services to accelerate the benefits of the FTA [3] - The customs authority has provided one-on-one policy guidance, enabling companies to utilize tariff reductions effectively, exemplified by a local company saving 44,000 yuan in taxes through zero-tariff clearance for imported machinery parts [3] - The implementation of a "single window" and smart customs initiatives has improved trade facilitation, reducing the time and costs associated with customs clearance and certificate application processes [3] Group 3 - Yanji Customs is committed to deepening the implementation of FTA policies and enhancing customs facilitation measures to support Jilin enterprises in integrating more deeply into China-South Korea economic and trade cooperation [4]

Market Overview - The three major indices showed mixed performance, with the Shanghai Composite Index rising by 0.49% to 4160.01, the Shenzhen Component Index increasing by 0.09% to 14342.74, and the ChiNext Index declining by 0.37% to 3330.39 [1][2]. Sector Performance - Precious metals, industrial metals, and petrochemicals sectors performed strongly, while solar energy, pharmaceuticals, and aerospace sectors experienced fluctuations [2]. - The basic metals sector saw significant gains, with copper and aluminum industries leading the rise, as multiple stocks hit the daily limit up [6]. Stock Highlights - Notable stocks included China National Offshore Oil Corporation, China Petroleum, and China Unicom, which showed strong performance [4]. - The aluminum futures market saw a rise of over 4%, with the main contract reported at 25345 yuan/ton [8]. Biotechnology Sector - The biotechnology sector faced declines, with several companies such as Zhijiang Biology and Baipusais losing over 9% [10][11]. Solar Energy Sector - The solar energy sector faced downward adjustments, with companies like High Measurement and Maiwei experiencing drops exceeding 6% [11].

尼帕病毒 （ Nipah virus，NiV ） 属于 副黏病毒科 ， 与 亨德拉病毒 （ Hendra virus, HeV ） 同属， 是 一种人畜共患病毒，这意味着它可以从动物传播给人类。 近日，印度 西孟加拉邦 出现 尼帕病毒 感染病例，近百人被要求居家隔离。据新闻报道，本次疫情或来自 医院，患者 A 因 误食被蝙蝠污染的新鲜椰枣汁造成感染 。受此影响，泰国和尼泊尔相继加强对来自印度 旅客的筛查措施。 我国已将尼帕病毒纳入《国境卫生检疫法》监测目录，目前尚未报告过相关病例。 尼帕病毒 （ Nipah virus，NiV ） 是一种新兴的、高致病性的副粘病毒 ，于 1998 年首次在马来西亚暴 发。因其高病死率 （ 40%-75% ） 、人畜共患、潜伏期长等特性，被 WHO 列为重点研究的病原体。 目前尚无专门针对尼帕病毒的疫苗和有效疗法，但科研人员正在积极进行验证，部分疫苗或候选药物已进 入临床研究阶段。 G 蛋白 和 F 蛋白 依然是其研发的核心靶点。 义翘神州 深耕病毒试剂开发领域 18 年， 已构建包含 6000 多种科研试剂的 ProVir® 病毒解决方案， 现货供应尼帕病毒相关重组蛋白和抗体 ...

● 本报记者葛瑶 国际资本对中国市场的关注度显著回升。去年境外投资者对中国市场的低配幅度从约2.5%收窄至约 1.3%，减少了约1.2个百分点的低配。瑞银全球金融市场交易部主管贺立言(Neil Hosie)日前在接受中国 证券报记者专访时表示："如果外资进一步降低低配幅度，将意味着可观的潜在资金流入。" 贺立言表示，外资情绪正从此前的观望态度转向"谨慎乐观"。在他看来，中国市场估值优势凸显、企业 治理持续改善、科技创新动能不断增强，叠加全球投资者分散化配置需求上升，配置型资金的入场窗口 有望逐渐打开。瑞银预计中国股市2026年全年涨幅约18%，盈利增速约10%，机器人、人工智能、新能 源汽车、生物科技等科技创新赛道最受关注。 外资谨慎乐观 "谨慎但乐观"，贺立言用这一表述来概括当前外资的情绪基调。他观察到，与一年前同期相比，境外投 资者的心态已发生明显转变。"今年投资者正在做大量工作来深入了解中国公司，这和去年年初相比已 经有了很大不同。"他认为，这一变化在一定程度上受2025年A股市场表现带动：上证指数全年涨幅达 18.41%，沪深300指数涨幅超17%，强劲的市场表现开始吸引全球投资者关注。 交易型资金活 ...

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with the World Health Organization classifying it as a deadly zoonotic virus with a mortality rate of 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical Holdings Limited is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for the prevention and control of emerging infectious diseases [1] - The company’s subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., is a high-tech enterprise established through a strategic investment with Carbon Cloud Intelligence, focusing on molecular diagnostics and offering comprehensive solutions in research, production, and technical services [1] Group 2: Technological Solutions - Carbonhua Biotechnology has developed a dual-platform detection solution for Nipah virus, capable of supporting the entire process from rapid screening to precise tracing [1] - The intelligent fluorescent PCR rapid detection platform utilizes an AI primer design platform, integrating gene retrieval, automated primer design, and multi-dimensional performance evaluation, achieving rapid and accurate detection of high-risk pathogens like Nipah virus [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution covering both "wet experiments and dry analysis," enabling simultaneous detection and differentiation of Nipah virus and other co-existing pathogens [4] Group 3: Strategic Development - The rapid deployment of Nipah virus detection capabilities reflects the technological strength of Carbonhua Biotechnology and is a significant step in Huajian Medical's overall AI healthcare strategy [6] - The company is advancing its acquisition of Chuangye Huikang Technology Co., Ltd., aiming to establish a next-generation public health prevention paradigm that integrates AI early warning, rapid diagnosis, and ecological collaboration [6] - The product launch and strategic articulation demonstrate the company's commitment to the core paradigm of "intelligent capital driving continuous profit from knowledge," enhancing innovation efficiency and commercial value within its ecosystem through technology integration, data collaboration, and capital empowerment [6]